Shorts

Remission Rates in the First 2 Weeks of Treatment

The Explosion of Alzheimer's Drug Research

Breaking Mental Health Stigma in Communities of Color

Switching ADHD Medications Effectively

Can Sleeping Pills Treat Alzheimer Disease?

Why Sleep Is Critical for Psychiatric Health

Targeting Sleep Quality in Depression

Why ADHD Meds Don't Always Help Mood Swings

The Math Behind Patient Benefits in Clinical Trials

How Genetics and Sleep Quality Predict Early Alzheimer Disease

New ADHD Treatment: Beyond Stimulants

Why We Need Expanded Access

Seltorexant vs Quetiapine Adjunct for MDD

What Makes This ADHD Drug Potentially Unique

The Biggest Challenge in Treating Alzheimer Disease

Morning Coffee and Updates: The Approval of Centanafadine for ADHD

Impact of Placebo & Patient Expectations on Medication Outcomes

Is Alzheimer Disease Actually Type 3 Diabetes?

Late Responders in Long Term Treatment With Austedo for Tardive Dyskinesia

The Placebo Effect at Work in Psychopharmacology

FDA Approves Centanafadine: A New Frontier in ADHD Treatment

Expanding the Neurotransmitter View of Depression

Discussing LAIs Candidly With Patients

COMP360, Synthetic Psilocybin, Shows Enduring Benefit

Financial Barriers to Neuromodulation Access

Impacts of Tribalism in Psychiatry

Mental Health Awareness & Advancing Cholinergic Agents

Barriers to Access in Postpartum Care

Assisting Treatment Outside of Psychiatric Care

Zolpidem Slows Alzheimer Progression in Animal Studies